The helicase-like transcription factor is a strong predictor of recurrence in hypopharyngeal but not in laryngeal squamous cell carcinomas

Histopathology

Volumn 55, Issue 1, 2009, Pages 77-90

  Capouillez, Aurélie ^a   Debauve, Gael ^a   Decaestecker, Christine ^b   Filleul, Olivier ^a   Chevalier, Dominique ^c   Mortuaire, Geoffrey ^c   Coppée, Frederic ^a   Leroy, Xavier ^d   Belayew, Alexandra ^a   Saussez, Sven ^a  

^a UNIVERSITY OF MONS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Department of Oto Rhino Laryngology ^*  (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Head and neck carcinoma; HIP 116; HLTF; Prognosis; SMARCA 3; SWI SNF protein; ZBU 1

Indexed keywords

HELICASE LIKE TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA REPAIR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; EPITHELIUM; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS;

EID: 68049146048     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03330.x     Document Type: Article

References (35)

1. Ferris RL. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J. Otorhinolaryngol. Relat. Spec. 2004 66 332 340.
2. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohia S. Head and neck cancer: meeting summary and research opportunities. Cancer Res. 2004 64 8126 8129.
3. Shah JP, Patel SG. Head and neck surgery and oncology. New York : Mosby, 2003.
4. Posner MR, Hershock DM, Blajman CR et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 2007 357 1705 1715.
5. Vermorken JB, Remenar E, van Herpen C et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007 26 2157 2165.
6. Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas (HNSCCs). Head Neck 2007 29 874 884.
7. Debauve G, Capouillez A, Belayew A, Saussez S. HLTF and its implication in cancer progression. Cell. Mol. Life Sci. 2008 65 591 604.
8. Moinova HR, Chen WD, Shen L. HLTF gene silencing in human colon cancer. Proc. Natl Acad. Sci. USA 2002 99 4562 4567.
9. Versteege I, Sevenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998 394 203 206.
10. Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. Aberrant methylation of HLTF, SOCS-1, and CDH13 genes is shown in colorectal cancers without lymph node metastasis. Dis. Colon Rectum 2005 48 1282 1286.
11. Hibi K, Nakao A. Highly-methylated colorectal cancers show poorly-differentiated phenotype. Anticancer Res. 2006 26 4263 4266.
12. Hibi K, Nakao A. Lymph node metastasis is infrequent in patients with highly-methylated colorectal cancer. Anticancer Res. 2006 26 55 58.
13. Hibi K, Nakayama H, Kanyama Y et al. Methylation pattern of HLTF gene in digestive tract cancers. Int. J. Cancer 2003 104 433 436.
14. Kim YH, Petko Z, Dzieciatkowski S et al. CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 2006 45 781 789.
15. Hamai Y, Oue N, Mitani Y et al. DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci. 2003 94 692 698.
16. Kim JJ, Chung SW, Kim JH et al. Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Ann. Oncol. 2006 17 657 662.
17. Leung WK, Yu J, Bai AH. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer. Mol. Carcinog. 2003 37 91 97.
18. Oue N, Mitani Y, Motoshita J et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006 106 1250 1259.
19. Fukuoka T, Hibi K, Nakao A. Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. Anticancer Res. 2006 26 3333 3335. (Pubitemid 44701505)
20. Kang S, Kim JW, Kang GH et al. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int. J. Cancer 2006 118 2168 2171.
21. Gong X, Kaushal S, Ceccarelli E et al. Developmental regulation of Zbu1, a DNA-binding member of the SWI2/SNF2 family. Dev. Biol. 1997 183 166 182.
22. Unk I, Hajdú I, Fátyol K et al. HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. Proc. Natl Acad. Sci. USA 2008 105 3768 3773.
23. Debauve G, Nonclercq D, Ribaucour F et al. Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis. Mol. Cancer 2006 5 23.
24. Ding H, Descheemaeker K, Marynen P et al. Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene. DNA Cell Biol. 1996 15 429 442.
25. Hyams VJ, Batsakis JG, Michaels L (eds) Tumors of the upper respiratory tract and ear. In Atlas of tumor pathology. Washington, DC : Armed Forces Institute of Pathology, 1998 132 137.
26. Wittekind C, Greene FL, Hutter RRP, Kimpfinger M, Sobin LH. TNM atlas, 5th edn. Berlin : UICC Springer, 2004.
27. Saussez S, Decaestecker C, Lorfevre F et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008 52 483 493.
28. Capouillez A, Decaestecker C, Filleul O et al. Helicase-like transcription factor exhibits increased expression and altered intracellular distribution during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Virchows Arch. 2008 453 491 499.
29. Saussez S, Cucu DR, Decaestecker C et al. Galectin-7 (p53-induced gene-1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann. Surg. Oncol. 2006 13 999 1009.
30. Hayward-Lester A, Hewetson A, Beale EG, Oefner PJ, Doris PA, Chilton BS. Cloning, characterization, and steroid-dependent posttranscriptional processing of RUSH-1 alpha and beta, two uteroglobin promoter-binding proteins. Mol. Endocrinol. 1996 10 1335 1349.
31. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007 26 2157 2165.
32. Courtois S, de Fromentel CC, Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 2004 23 631 638.
33. Shah J. Head and neck surgery and oncology. London : Mosby, 2003.
34. Roland NJ, Caslin AW, Nash J et al. Value of grading squamous cell carcinoma of the head and neck. Head Neck 1992 14 224 229.
35. Audet N, Beasly NJ, MacMillan C et al. Lymphatic vessel density, nodal metastases and prognosis in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2005 131 1065 1070.